Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

Author： Wan George J.   Kozma Chris M.   Slaton Terra L.   Olson William H.   Feagan Brian G.  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.17, Iss.6, 2014-06, pp. : 384-393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bipolar, MDD patients non‐adherent to antipsychotic meds

By  

MENTAL HEALTH WEEKLY, Vol. 25, Iss. 26, 2015-06 ,pp. : 6-7

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1133-1133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions. Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 9, 2015-11 ,pp. : 1134-1134

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions. Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 9, 2015-11 ,pp. : 1134-1134

John Wiley & Sons Inc

Access to resources Recommend Favorite